Compare ENSG & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENSG | PRAX |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 8.8B |
| IPO Year | 2007 | 2020 |
| Metric | ENSG | PRAX |
|---|---|---|
| Price | $173.59 | $309.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 15 |
| Target Price | $196.40 | ★ $503.93 |
| AVG Volume (30 Days) | 325.0K | ★ 599.2K |
| Earning Date | 02-04-2026 | 02-27-2026 |
| Dividend Yield | ★ 0.15% | N/A |
| EPS Growth | ★ 35.03 | N/A |
| EPS | ★ 5.59 | N/A |
| Revenue | ★ $4,829,467,000.00 | $7,463,000.00 |
| Revenue This Year | $21.25 | N/A |
| Revenue Next Year | $12.54 | $15,003.90 |
| P/E Ratio | $30.87 | ★ N/A |
| Revenue Growth | 17.55 | ★ 364.98 |
| 52 Week Low | $118.73 | $26.70 |
| 52 Week High | $194.00 | $326.91 |
| Indicator | ENSG | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 46.38 | 57.00 |
| Support Level | $167.43 | $304.03 |
| Resistance Level | $172.29 | $323.40 |
| Average True Range (ATR) | 4.81 | 19.01 |
| MACD | -0.43 | -2.11 |
| Stochastic Oscillator | 36.61 | 63.51 |
Ensign Group Inc provides post-acute healthcare services in the United States. Its regional subsidiaries oversee skilled nursing, assisted living, home health and hospice, mobile ancillary, and urgent care operations. Medicare and Medicaid programs contribute majority of revenue received for Ensign's services. The firm operates through two segments, Skilled services, and Standard Bearer. The skilled services segment includes the operation of skilled nursing facilities and rehabilitation therapy services. The Standard Bearer segment comprises of properties owned by the company through its captive REIT and leased to skilled nursing and assisted living operations. The majority of the revenue is generated from the skilled services segment.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.